2seventy Bio, Inc.

Regeneron Pharmaceuticals, Inc.

Bluebird Bio, Inc.

Novo Nordisk A/s

Kyle Havens

Jordan Jarjour

Anne-Rachel Krostag

Michael Certo

Max Echterling

Constantine Chrysostomou

The present disclosure provides homing endonuclease variants and megaTALs reprogrammed to bind and cleave a polynucleotide sequence in the genome. The homing endonuclease variants and megaTALs have been engineered to increase the thermostability and/or activity.

Homing endonuclease variants

The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.

CBLB endonuclease variants, compositions, and methods of use

The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.

PCSK9 endonuclease variants, compositions, and methods of use

The present disclosure provides improved genome editing compositions and methods for editing a TGF&#x3b2;R2 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.

Growing community of inventors

Seattle, WA, United States of America

Kyle Havens